



October 30, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051

Dear Sir/Madam,

**Re: Disclosure pursuant to Regulation 30 of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

Subject: US FDA Inspection of the Company's Nagpur Unit-2 injectable manufacturing facility

We would like to inform you that the US FDA inspected Lupin's Nagpur Unit-2 injectable manufacturing facility from October 17, 2022 to October 29, 2022. The inspection was a Pre-Approval Inspection of the injectable facility. The inspection closed with issuance of a Form-483 with five observations.

We are committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the U.S.

This may kindly be considered as a disclosure pursuant to Regulation 30 of Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**